Drug intelligence / Profile preview

OS2966-LOCAL

Development stage: Preclinical
Lead developer: OncoSynergy
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Topical, Focal Delivery

Overview

OS2966-LOCAL is a monoclonal antibody developed by OncoSynergy that targets CD29 (also known as Integrin beta-1). This specific formulation or delivery approach is designed for local or focal administration, distinguishing it from systemic versions of the same antibody. By binding to CD29, the antibody modulates local pathology by blocking integrin-mediated signaling pathways involved in inflammation, tissue remodeling, and cellular migration. OS2966-LOCAL is currently in preclinical development for the treatment of psoriasis and traumatic brain injury (TBI), where it is intended to modulate local disease pathology through targeted inhibition of integrin signaling.

Targets

ITGB1 (Integrin beta-1)

Beyond the preview

Go deeper on OS2966-LOCAL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OS2966-LOCAL.

Explore the full profile